Lupin Bioresearch Center receives zero observations from US-FDA

New Delhi: Global pharma major Lupin Limited has announced that the United States Food and Drug Administration (U.S. FDA) has completed an onsite clinical inspection from November 3 to November 6, 2025, at its Bioresearch Centre in Pune that concluded with zero 483 observations.

A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations.

Nilesh Gupta, Managing Director, Lupin, said, “The successful outcome of the onsite clinical inspection and bio-analytical assessment by the U.S. FDA at our Bioresearch Centre is testament to our ongoing commitment to quality and compliance.  We remain focused on improving the lives of our patients globally.”